MedTrace Logo

Using Device Delivering Ophthalmic Solution in a Spray Form Instead of Eye Drops

NCT00565630 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2009-02-25

No results posted yet for this study

Summary

The purpose of the study is to confirm that Vigamox reaches similar aqueous concentration when administered as the commercially available eye drops or as a spray delivered from a proprietary device.

Conditions

  • Cataract

Interventions

DEVICE

Vigamox delivered via the device in spray form

Vigamox delivered 4 times, 1 hour prior to cataract surgery

Sponsors & Collaborators

  • Advanced Ophthalmic Pharma

    lead INDUSTRY

Principal Investigators

  • Adi Michaeli, MD · Dept of Ophthalmology, TAMC, Tel Aviv, Israel

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Completion
2008-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00565630 on ClinicalTrials.gov